Tamar Securities’s Fennec Pharmaceuticals FENC Stock Holding History

Tamar Securities’s Portfolio FENC Stock Details FENC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-53,475	Closed	-$513K	–	68
2022 Q4	$513K	Hold	53,475	–	–	0.16%	38
2022 Q3	$433K	Hold	53,475	–	–	0.14%	43
2022 Q2	$302K	Hold	53,475	–	–	0.1%	47
2022 Q1	$299K	Hold	53,475	–	–	0.08%	50
2021 Q4	$235K	Buy	+53,475	New	+$398K	0.07%	53

Other funds holding FENC

SCA

Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return

SGL

Sonic GP LLC Honolulu, Hawaii $45.4M AUM 5.08% 1-Year Est. Return

SCM

Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return

DCM

DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

HFA

Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

GJL

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Tamar Securities's FENC Position: Q1 2023 in Review

Tamar Securities sold out of Fennec Pharmaceuticals (FENC) in Q1 2023, closing a stake of 53,475 shares — an estimated $513K sold.

Tamar Securities first reported a position in FENC in Q4 2021 and held it in 5 quarters. The position peaked at $513K in Q4 2022. 53 funds tracked by Wall St. Rank hold FENC as of Q1 2023.

Tamar Securities reported no remaining Fennec Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Tamar Securities sold 53,475 Fennec Pharmaceuticals shares in Q1 2023, an estimated $513K.
Tamar Securities first reported a position in Fennec Pharmaceuticals in Q4 2021 and held it in 5 quarters.
Tamar Securities's Fennec Pharmaceuticals position peaked at $513K in Q4 2022.
53 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q1 2023.

Based on Tamar Securities's 13F filing for Q1 2023, filed 10 Oct 2024.